The last decade has witnessed a transformation in the treatment of advanced-stage lung
cancer from a largely palliative approach to one where long-term durable remissions and …

Simple Summary Despite an initial response to therapy, many lung cancer patients
inevitably develop resistance to therapy leading to decreased duration of response and …

In the past decade, a shift toward targeted therapies in non-small-cell lung cancer following
molecular profiling has dramatically changed the way advanced adenocarcinoma is treated …

Targeted therapies for cancer bring the hope of specific treatment, providing high efficacy
and in some cases lower toxicity than conventional treatment. Although targeted …

Despite a growing interest in development of non-cytotoxic targeted agents, systemic
chemotherapy is still the mainstay of treatment for both non-small cell lung cancer (NSCLC) …

The biggest hurdle to targeted cancer therapy is the inevitable emergence of drug
resistance. Tumor cells employ different mechanisms to resist the targeting agent. Most …

The advent of genomics has led to the identification of specific “driver” mutations in
oncogenic kinases, and the development of targeted small molecule inhibitors to block their …

Despite the tremendous efforts for improving therapeutics of lung cancer patients, its
prognosis remains disappointing. This can be largely attributed to the lack of comprehensive …

Lung cancer is one of the most deadly diseases worldwide. The current first-line therapies
include chemotherapy using epidermal growth factor receptor tyrosine kinase inhibitors and …

The drug resistance limits the optimal efficacy of drugs during target therapies for lung
cancer and requires the development of precision medicine to identify and develop new …